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Fibroblast growth factor-10 (FGF10) is a mesenchymal growth
factor, involved in epithelial and mesenchymal interactions during
lung branching morphogenesis. In the present work, FGF10 over-
expression was transiently induced in a temporally and spatially
restrictedmanner, during the pseudoglandular or canalicular stages
of rat lung development, by trans-uterine ultrasound-guided intra-
parenchymal microinjections of adenoviral vector encoding the
rfgf10 transgene. The morphologic and histologic classification of
the resulting malformations were dependent upon developmental
stage and location. Overexpression of FGF10 restricted to the prox-
imal tracheobronchial tree during the pseudoglandular phase
resulted in large cysts lined by tall columnar epithelium composed
primarily of Clara cells with a paucity of Type II pneumocytes,
resembling bronchiolar type epithelium. In contrast, FGF10 over-
expression in the distal lung parenchyma during the canalicular
phase resulted in small cysts lined by cuboidal epithelial cells
composed of primarily Type II pneumocytes resembling acinar epi-
thelial differentiation. The cystic malformations induced by FGF10
overexpression appear to closely recapitulate the morphology and
histology of the spectrum of human congenital cystic adenomatoid
malformation (CCAM). These findings support a role for FGF10 in
the induction of human CCAM and provide further mechanis-
tic insight into the role of FGF10 in normal and abnormal lung
development.
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Fibroblast growth factors (FGFs) comprise a family of potent
mitogens that regulate cellular proliferation, migration, and
differentiation (1, 2). Two members of the FGF family, FGF7
and FGF10, are expressed in lung mesenchymal cells in dis-
tinct spatial and temporal patterns. FGF7 expression begins
at Embryonic Day (E)14.5 and is expressed throughout the
mesenchyme surrounding the developing lung tubules (3, 4).
FGF10 expression is initiated earlier at the onset of lung organ-
ogenesis and is restricted to the mesenchyme surrounding the
distal tips of the branching tubules (5). Both FGF7 and FGF10
bind with high affinity to the same FGF receptor isoform,
FGFR2b (6, 7). FGFR2 expression is restricted to the epithelial
cells of the developing lung at the onset of lung organogenesis
at E9.5, and moves more peripherally in epithelial distribution
with ongoing lung development (7). These distinct patterns of
expression of FGF7 and FGF10 in lung mesenchyme and the
simultaneous expression of FGFR2 in respiratory epithelial
cells implicate a primary role for FGF mesenchymal/epithelial
signaling in lung morphogenesis. The control of the bud size and
shape during branching is achieved by an intricate exchange of
signals between the growing bud and the surrounding mesen-
chyme. As the bud elongates, FGF10/FGFR2 signaling induces
expression of Spry2 and Bmp4 in the distal epithelium. Spry2 is
one of the earliest factors to be induced and limits the pro-
liferation of the lung epithelium (8, 9). Bmp4 disrupts distal
budding when expression is activated via an autocrine mecha-
nism (10, 11).
Much of what is currently known about the role of the FGFs
and other individual mediators of lung morphogenesis has been
derived from analysis of phenotypes induced by either targeted
disruption, or ectopic transgenic overexpression of the candi-
date genes. Targeted disruption of fgf10 results in absence of
lung structures distal to the mainstem bronchi, and this pheno-
type is replicated in fgfr2b knockout mice, confirming a critical
role for this signaling pathway in lung development (12, 13). In
contrast, mice with targeted disruption of fgf7 have normal
lungs (14), indicating that this polypeptide is not required for
normal lung morphogenesis or that the FGF peptides have
redundant functions. Ectopic overexpression of either factor in
respiratory epithelium using epithelium specific promoter genes
results in marked perturbations of lung morphogenesis. FGF7
overexpression is uniformly lethal by E16, inducing massive
cysts of the pulmonary parenchyma reminiscent of the macro-
cystic form of cystic adenomatoid malformation (15). Condi-
tional ectopic overexpression of FGF10 in the respiratory
epithelium at later stages of gestation markedly perturbs lung
morphogenesis and causes dense, adenomatous malformations
(16). These effects appear to be mediated by the proliferative
and chemoattractant effects of FGFs on lung epithelium. FGF7
has potent mitogenic effects on pulmonary epithelial cells
inducing proliferation of bronchial epithelial and mature type
II alveolar cells (4, 17). FGF10 acts as a mitogen and chemo-
attractant, inducing directional growth of the lung buds in close
proximity (5, 18, 19) during the earliest stages of lung de-
velopment. While the above studies are elucidating in many
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ways, they also emphasize that the effects of specific lung
growth factors on normal or abnormal lung development are
highly dependent upon timing, duration, and distribution of
expression. Global, ectopic expression of these highly spatially
and temporally restricted growth factors may induce artifactual
effects not seen with more compartment-appropriate overex-
pression, including autocrine effects and absence of normal
directional induction. We reasoned that a more physiologic and
discrete approach to dissection of FGF10 effects on lung devel-
opment would be to induce transient, mesenchymal, overexpres-
sion in a localized area of the developing lung during specific
stages of lung development.
We recently described an efficient method for gene transfer
to fetal lung interstitial cells during the pseudoglandular stage
of lung development by direct ultrasound-guided intrapulmo-
nary injection of viral vectors (20). Furthermore, we demon-
strated that adenoviral vector induced a rapid onset but relatively
transient expression of the reporter gene relative to lentiviral
vector. It occurred to us that this model might be valuable
for investigation of the effects of transient and localized mes-
enchymal overexpression of specific growth factors on lung
development.
In the present work, we hypothesized that focal FGF10
mesenchymal overexpression during lung development would
cause focal abnormalities of epithelial proliferation. To test this
hypothesis, we injected a bi-cistronic adenoviral vector encod-
ing the rfgf10 and egfp transgenes (AdGFP-FGF10) into targeted
areas of fetal rat lung parenchyma, at specific stages of lung
development. We observed that FGF10 overexpression resulted
in the induction of consistent patterns of malformation, the
appearance of which were developmental stage and location
dependent. These malformations, in total, appear to closely reca-
pitulate the morphology and histology of the entire spectrum of
human congenital cystic adenomatoid malformation (CCAM).
MATERIALS AND METHODS
All experimental protocols were approved by the Institutional Animal
Care and Use Committee at the Children’s Hospital of Philadelphia
and followed guidelines set forth in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Viral Vector Preparation
Cell culture. 293 cells were kindly provided by the Gene Therapy
Program (Division of Medical Genetics, University of Pennsylvania,
Philadelphia, PA). Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies/Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT),
100 units/ml penicillin, and 100 mg/ml streptomycin (Life Technologies/
Invitrogen) at 378C in a 5% CO2 humidified atmosphere.
Rat FGF10 cds and recombinant adenovirus constructions.
A cDNA library was prepared from newborn Sprague-Dawley lung
using Trizol Reagent and Superscript (Invitrogen, Carlsbad, CA) as per
manufacturers’ recommendations. The rat FGF10 cds was amplified
using the forward primer 59-gcggccgcc atgtggaaatggatactgacacattg-39
and reverse primer 59-ctcgaggctagcctatgagtggaccaccatg-39 using stan-
dard methods and confirmed by sequence analysis (GenBank Sequence
Database accession number NM_012951). The first-generation recom-
binant human adenovirus serotype 5 vector expressing the rat FGF10
cds was synthesized as previously reported (21) with the following
modifications. The rat FGF10 cds was subcloned into a previously
modified pShuttle-CMV vector containing a multiple cloning site and
IRES-GFP cassette downstream to the promoter. Approximately 1 mg
of the PmeI linearized shuttle vector DNA was electroporated into
Escherichia coli BJ5183 harboring the pAdEasy-1 vector. Selected
colonies were screened by restriction digests for the presence of size
correct homologous recombined plasmids. The pAd-CMV-Rat FGF10-
IRES-GFP plasmid DNA transformed the recA–E. Coli, DH10B, by
electroporation for large-scale amplification. Five micrograms of PacI-
linearized pAd-CMV-Rat FGF10-IRES-GFP DNA was combined with
Maxfect (Mediatech, Herndon, VA) as per manufacturer’s instructions
and used to transfect 293 cells. Transfected cells were monitored for
GFP expression and cytopathic effect. Twelve days later, cells and cell
debris were removed, pelleted, and after three cycles of freeze/thawing
a viral lysate was obtained, identified as Ad-ratFGF10. To assure the
production of rat FGF10 protein, 293 cells were infected with the viral
lysate, and 48 hours later growth media was assayed for the presence of
rat FGF10 by Western blot using a rabbit anti-Rat FGF10 antibody (H-
121:sc-7919; Santa Cruz Biotechnology, Santa Cruz, CA) at 1/200
dilution. Propagation, concentration, and purification of the Ad-
ratFGF10 was performed using Vivapure AdenoPACK 500 kit (Sar-
torius, Edgewood, NY) following manufacturer’s recommendations.
The viral pellet was resuspended in storage buffer (20 mM Tris-HCl,
25 mM NaCl, 2.5% glycerol, pH 5 8) and stored at 2808C. Titer was
determined in triplicate using serial dilutions of viral stock on 293 cells.
Two days later, titers were determined by counting the number of
GFP-positive colonies/field.
Ultrasound-Guided Injections
Time-dated pregnant Sprague-Dawley (Charles-River, Boston, MA)
rats at 15.5 (E15.5; n 5 42) and 18.5 (E18.5; n 5 18) days post-coitum
were anesthetized and a laparotomy was performed. Ultrasound-guided
injections were performed as previously described (20). Briefly, fetuses
were positioned to obtain axial views of the lungs in B-mode (Visual-
Sonics, Toronto, Canada). The tip of the micropipette was brought into
the image plane and was physically advanced through the uterine wall
and amniotic cavity into the lung. A volume of 25 nl was injected using
a remote control injector. After injections, damswere allowed to recover
in a warming chamber. Two types of injections were performed with re-
spect to the level of the bronchopulmonary tree. Injections performed
near the main bronchus were defined as proximal. Injections performed
at the peripheral basal area of the lung were defined as distal.
Ultrasound and Magnetic Resonance Imaging
Fetuses to be analyzed at E16.5, E18.5, and E21.5 were first inspected
for lung morphology by ultrasound biomicroscopy. After performing
laparotomy, the uterus was partially removed from the abdomen
exposing one or two fetuses. Fetuses were covered with warmed sterile
ultrasound gel and positioned to obtain axial views of the lungs in B-
mode using a 40-MHz probe (VisualSonics).
Lung morphology of pups 1 week old (P7) was examined by
magnetic resonance imaging using a Bruker Advance 400 wide-bore
NMR spectrometer (Bruker AXS Inc., Madison, WI) equipped for
microimaging. The Bruker self-shielded gradients were used with a
25-mm-diammeter RF coil to image the whole pups. After isoflurane
overdose and neck dislocation, lungs were instilled intratracheally with
perfluorocarbon to increase contrast and reduce susceptibility artifacts.
Pups were inserted vertically into an 18-mm glass tube filled with
Fomblin (perfluoropolyether), a liquid that approximately matches the
susceptibility of tissue and does not give any background signal. Axial,
coronal, and sagittal slices through the thoracic cavity were acquired
with a spin echo T2 weighted pulse sequence, in which each image
represents the sum of four echoes. For each orientation, 16 contiguous
slices of 0.5 mm thickness were acquired with a square field of view
(FOV) of 18 mm, a square matrix of 256 3 256 giving an in-plane
resolution of 70 mm2. The images were acquired using the following
parameters: bandwith 50 kHz, pulse length 2 ms, repetition time 2 s,
echo time 12 ms, and 2 excitations. Fetuses were screened inside the
uterus at E16.5, E18.5, E19.5, and E21.5 dpc, and after being
anesthetized, at 1 week (P7). The fetuses were positioned to get axial
views of the lungs in B-mode and were screened in 3D-mode. After
screening, fetuses and pups were harvested and lungs collected for
stereomicroscopy, histology, and biochemical analysis.
Stereomicroscopy
Injected fetuses were visualized under a fluorescence stereomicroscope
(MZ16FA; Leica, Heerburgg, Switzerland) immediately after harvest-
ing, to evaluate enhanced green fluorescent protein expression, trans-
duction efficiency, and biodistribution of the vector within lungs,
trachea, heart, and diaphragm.
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Histology and Immunohistochemistry
Specimens for histologic analysis were fixed in formalin (10%) and
processed for paraffin sections. Immunostainings were performed on
4-mm-thick paraffin-embedded sections. After dewaxing in xylene and
rehydration in ethanol, slides were blocked for specific serum (1:10
dilution) for 30 minutes at room temperature (RT) followed by
incubation at 48C with each primary antibody. The primary antibodies
weremonoclonal mouse EPOS anti–a-SMA (U.7033; Dako, Carpinteria,
CA), polyclonal rabbit anti–Clara cell secretory protein (CCSP) (1:800
dilution;SevenHillsBioreagents,Cincinnatti,OH),polyclonal rabbit anti-
pro–surfactant protein (SP)-C (1:100 dilution; Chemicon, Temecula, CA),
and polyclonal rabbit anti-GFP (1:100 dilution; Invitrogen). Samples were
incubatedwith 3%hydrogen peroxide inmethanol for 30minutes at room
temperature to quench endogenous peroxidase. Incubation with second-
ary antibody biotinylated goat anti-polyvalent (UltraVision HRP De-
tection System; Lab Vision, Fremont, CA) was performed at room
temperature for 30 minutes. Slides were incubated with avidin–biotin
complex (1:200 dilution; Vector Laboratories, Burlingame, CA) and
developed with 3, 39-diaminobenzidine (DAB) substrate kit (SK-4100;
Vector Laboratories). Sections were counterstained with Harris hema-
toxylin. The sections were visualized under the Olympus BX61 micro-
scope and photographed using an Olympus DP70 camera (Olympus
America, Center Valley, PA). Adjacent sections were also stained with
hematoxylin and eosin for morphologic studies.
In Situ Hybridization
Digoxigenin-labeled rat FGF10 antisense and sense probes were pro-
duced from the 648-bp sequence cloned in pIBI31, linearized using
NheI or NotI, and transcribed with T3 or T7 polymerases, respectively.
The following mouse cDNAs were used to generate digoxigenin-
labeled riboprobes: 1.0 kb Bmp4 and 948 bp Spry2 (kindly provided
by Dr. Saverio Bellusci). Lungs were fixed overnight at 48C in 4%
formaldehyde-2 mM EGTA, rinsed in PBS, dehydrated through a
methanol series, and stored in 100% methanol at2208C. Whole-mount
(FGF10) and tissue section (BMP4 and Spry2) in situ hybridization
were performed according to procedures described previously (22, 23).
Lungs were visualized as whole mounts in PBT (PBS, 0.1% Tween20)
under a dissecting microscope stereomicroscope and photographed
with an Olympus 2100 camera. Whole mount lungs were embedded in
2-hydroxyethyl methacrylate (Technovit 7100; Heraeus Kulzer GmbH,
Hanau, Germany) and processed for sectioning at 15 mm thickness
using a rotary microtome (Leica RM 2155). Hybridized lungs sections
were photographed using an Olympus DP70 camera coupled to an
Olympus BX61 microscope.
Quantitative PCR
Samples from injected lungs collected at E16.5, E18.5, and E21.5 were
placed in 1.5 ml microcentrifuge tubes, immediately frozen in liquid
nitrogen, and stored at 2808C.
To examine rFGF-10 gene expression, total RNA from each lung
specimen was isolated using TRIzol Reagent (Invitrogen, Carlsbad,
CA), reverse transcribed, and subjected to quantitative polymerase
chain reaction (qPCR) analysis as previously described (24–26). First-
strand cDNA was prepared from 1 mg total cellular RNA isolated
above. Total cDNA was used for the relative quantification by real
time-PCR of rFGF10 and of the reference gene, rb-actin, using the
ABI PRISM 7700 s Sequence Detection System (Applied Biosystems,
Foster City, CA). Sequence data were obtained from the GenBank Se-
quence Database (accession numbers: NM_031144, Rattus norvegicus
rb-actin; NM_012951, R. norvegicus FGF10 mRNA). Pre-designed
TaqMan Gene Expression Assays were used for rFGF10
(Rn00564115_m1; Applied Biosystems), b-actin (Rn00667869_m1;
Applied Biosystems). Amplification conditions were identical for all
reactions. The thermal profile was as follows: 2 minutes at 508C, 10
minutes of denaturation at 958C, 40 cycles of denaturation at 958C for
15 seconds, and annealing and extension at 608C for 1 minute. The
amplification reactions were set in a final volume of 20 ml, containing
13 TaqMan Universal PCR Mastermix (Applied Biosystems), 100 ng
of the cDNA sample, 900 nM of each primer, and 250 nM of the
respective probe. Negative control was included in all the runs, which
consisted of omitting the cDNA and performing a melting curve
analysis. b-actin, rFGF10, standard amplification curves (ST curve)
were made with randomly selected cDNA samples (setting at r5 0.99).
For each experimental group studied, three samples were analyzed, in
triplicate, and mean result was used for further analysis. Amplification
data were analyzed by the sequence detection system software (SDS
1.2 version; Applied Biosystems).
Statistical Analysis
The results were presented as mean 6 SE. To ascertain the statistical
significance of the differences in the levels of mRNA, one-way
ANOVA was performed. Upon statistically significant differences,
a Student-Newman-Keuls test was selected to perform pairwise
multiple comparisons. Survival rates were compared by the log-rank
test. Differences between groups were considered to be statistically
significant when P , 0.05.
RESULTS
Intraparenchymal Injection of AdGFP-FGF10 during the
Pseudoglandular Stage Results in Pulmonary Morbidity
We investigated the effects of localized FGF10 overexpression
on fetal rat lungs during the pseudoglandular and canalicular
stages of lung development by performing transuterine ultra-
sound-guided microinjections of AdGFP-FGF10 at E15.5 and
E18.5 by our previously described technique. Pre- and postnatal
imaging analysis revealed the presence of cystic lesions in the
injected lungs without obvious other abnormalities. External
morphology of injected fetuses among all the groups was
normal, as was the macroscopic structure of diaphragm, heart,
and thoracic cavity. At cesarean, we detected a prenatal mor-
tality rate of 26% and 10% associated with lung injections at
E15.5 and E18.5, respectively, with control PBS injections. This
was comparable to our previous study (20) using the same
methodology and comparing PBS with the identical AdGFP
vector minus the FGF10 transgene. In that study, survival to
cesarean section was 81 6 6% and 87 6 4% for PBS and
AdGFP, respectively. It is also important to note that in that
study, no pulmonary cystic changes were seen in any animals
injected with PBS or AdGFP vector alone. When AdGFP-
FGF10 was injected at E15.5, there was an additional mortality
during the first hours of postnatal life that reduced the survival
rate to 33% by the seventh day after birth. Some pups that were
injected at E15.5 were cyanotic and displayed gasping respira-
tory efforts within a few hours after birth, with subsequent
demise. Autopsies or magnetic resonance imaging (MRI) exam-
ination revealed very large cysts that occupied almost all of the
ipsilateral hemithorax. In contrast, when AdGFP-FGF10 was
injected at E18.5, the survival rate was not statistically different
from that of PBS-injected controls and no macrocystic lesions
were seen. Pups that survived until the seventh day after birth
displayed overtly normal activity levels and appeared develop-
mentally normal. There were no maternal deaths.
Phenotype of the Lung Cystic Malformation Is Developmental
Stage Dependent
To assess the effect of focal FGF10 overexpression on lung
development during critical periods of lung morphogenesis, we
performed in utero gene transfer during the rat pseudoglandular
(E15.5) and canalicular (E18.5) stages of lung development.
Lungs were analyzed by ultrasound, MRI, gross appearance,
and fluorescence stereomicroscopy at different pre and post-
natal time points (Figure 1).
When FGF10 gene transfer was performed at E15.5, mal-
formations containing large cysts were detected as early as 24
hours after injection (Figures 1a–1c). The malformations per-
sisted during the remainder of gestation (Figures 1d–1i) and at
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1 week after birth (Figures 1j–1l). Imaging of these lesions
revealed fluid-filled areas of low echogenicity with thin in-
tervening septa surrounded by normal lung parenchyma. Gross
inspection revealed lung malformations characterized by a single
or usually multiple large cysts that were lined by a thin mem-
brane. The cysts were always restricted to a single lobe of the
lung. Analysis by fluorescence stereomicroscopy demonstrated
that the affected area coincided with the area of gene transfer,
as confirmed by GFP expression. At birth after ventilation of
the neonatal lung, the cysts were immediately filled with air.
The communication between the main airways and the cysts was
confirmed by bronchofluoroscopy (data not shown).
In contrast, when FGF10 gene transfer was performed at
E18.5, prenatal ultrasound imaging revealed hyperechogenicity
in the area injected within 24 hours after injection, with only
rare instances of visible cysts by ultrasound or gross inspection
(Figures 1m–1r). These malformations were not easily detected
by gross inspection; however, postnatal MRI revealed restricted
areas with several small cysts (Figure 1s).
Phenotype of the Malformation Is Spatially Dependent
To explore the effect of FGF10 gene transfer at different levels
of the bronchopulmonary tree, injections localized to either the
proximal or the distal areas of the developing lung were
analyzed at term (E21.5) (Figure 2). When the injections were
performed at E15.5, proximal injections (Figures 2a–2c) in-
duced larger cysts than distal injections (Figures 2d–2f), but the
number of cysts were greater in the distal injection group. In
contrast, injections into either the proximal or distal lung paren-
chyma at E18.5 induced only small cysts on microscopic analysis
(Figures 2g–2l). Relative to the early injections, the affected
area was more restricted and no macroscopic cysts were clearly
seen. In all groups, lesions were well demarcated histologically
from the adjacent normal lung parenchyma.
Histologic Characterization of Induced Cystic
Lung Malformations
Specimens from lungs injected either at E15.5 or E18.5 were
harvested at E21.5 and processed for histologic analysis and
immunohistochemistry for a-smooth muscle actin (a-SMA),
CCSP, SP-C, and green fluorescence protein (GFP) (Figure 3
and Table 1). Lungs injected at E15.5 targeting the proximal
bronchopulmonary tree demonstrated one to four large predom-
inant cysts surrounded by normal lung parenchyma (Figures 3f–
3j). These cysts were lined by tall columnar pseudostratified
epithelium encircled by a well-defined muscular wall composed
of two to three cell layers. Most of the cells lining the cysts were
positive for CCSP, whereas only a few cells stained for pro–SP-C,
indicating a predominance of Clara cells and a paucity of Type
II pneumocytes, respectively. Cartilage and skeletal muscle
were absent. In lungs injected at E15.5 with gene transfer to the
distal lung parenchyma, several large cysts appeared in the
injected area which were lined with cuboidal to tall columnar
epithelium (Figures 3k–3o). Smooth muscle fibers could be
detected surrounding the cysts forming an incomplete layer.
Within the cysts there was a sharp boundary between positive
and negative areas for CCSP, corresponding to the transition be-
tween terminal and respiratory bronchioles. There was an in-
tense staining for pro–SP-C in the epithelial lining of the cysts.
Cystic malformations in fetuses injected at E15.5 were separated
by thin septa with only a small amount of interstitial tissue.
Injections targeting the proximal lung parenchyma at E18.5
resulted in multiple relatively small-size cysts compared with
the early injection time point (Figures 3p–3t). These cysts were
lined by cuboidal epithelium with few Clara cells and rare type
II pneumocytes. Smooth muscle fibers could be detected
surrounding the cysts forming an incomplete layer. Injections
targeting the distal lung parenchyma at E18.5 resulted in several
types of small cysts (Figures 3u–3y). Some resembled bron-
chioles, while others contained intricate folds. The lining
Figure 1. Developmental stage dependence of cystic malformations.
Fetuses injected at Embryonic Day (E)15.5 were analyzed at E16.5,
E18.5, E21.5, and Postnatal Day (P)7 (a–l ). Representative images of
injected lungs demonstrate macrocystic malformations (white arrows)
by ultrasound at prenatal time points and magnetic resonance imaging
(MRI) at P7. The macrocysts appeared within 24 hours after injection
(a–c) and persisted until P7 ( j–l ) and were large enough to be easily
appreciated by gross examination (red arrows). The expression of
enhanced green fluorescent protein (EGFP) coincided with the affected
area (c, f, i, l, green arrows). Fetuses injected at E18.5 were analyzed at
E19.5, E21.5, and P7 (m–u). Microcystic malformations were detected
by ultrasound at E19.5 (m) and E21.5 (p) as an area of increased
echogenicity (black arrowheads) and were visualized as small cysts on
MRI at P7 (s, white arrowheads). The malformations were present by
E19.5 and persisted until P7, with the area of the malformation
coinciding with the area of EGFP expression (o, r, u, green arrowheads).
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epithelium was composed primarily of type II pneumocytes.
Clara cells were absent. Expression of a-SMA revealed the
presence of scattered smooth muscle cells. Relative to the E15.5
injected group, fetuses injected at E18.5 displayed septa be-
tween the cysts that contained a moderate to abundant amount
of loose mesenchymal-type interstitium. As we noted in our
previous study (20) the distribution of gene transfer as con-
firmed by GFP immunohistochemistry (Figures 3j, 3o, 3t, 3y)
appeared to be restricted to the mesenchyme in all lungs
injected with AdGFP-FGF10.
Location and Quantification of Lung FGF10 Overexpression
FGF10 mRNA expression was detected by whole mount in situ
hybridization (wISH) 24 hours after injections in both the early
and late injected groups (Figures 4a–4o). The normal pattern of
FGF10 expression observed in the PBS-injected control lungs
was profoundly altered by FGF10 gene transfer. In all injected
lungs examined, an increase in FGF10 mRNA expression was
observed in an area that corresponded to the area of expression
of GFP. On tissue sections of hybridized lungs, FGF10 over-
expression in both early and late injected lungs appeared to
be restricted to the mesenchymal compartment of lung pa-
renchyma (Figures 4j and 4o), in agreement with the GFP
immunohistochemistry.
Quantification of FGF10 mRNA levels was performed at
E16.5, E18.5, and E21.5 in ipsilateral and contralateral lungs
injected at E15.5 and compared with PBS-injected control lungs
(Figure 4p). FGF10 mRNA expression was significantly in-
creased in only the injected lung at 24 hours after injection.
Levels of fgf10 mRNA in injected lungs returned to levels
measured in PBS control groups at E18.5 and E21.5.
Expression Pattern of BMP4 and Spry2 in
Cystic Malformations
The expression pattern of BMP4 and Spry2 was characterized
by in situ hybridization (ISH) 24 hours after injection in both
early and late injected lungs (Figure 5). For early injected lungs,
aside from the cystic morphology, the pattern of expression of
BMP4 and Spry2 did not seem significantly altered in compar-
ison with the PBS controls (Figures 5a–5d). In contrast, for late
injected lungs expression of BMP4 and Spry2 appears signifi-
cantly increased relative to controls in the epithelium of the
cystic malformations (Figures 5e–5h).
DISCUSSION
FGF10 overexpression from the mesenchyme was focally and
transiently induced at different locations and developmental
stages in the fetal rat lung using our method of intraparenchy-
mal gene transfer. In the area of forced FGF10 expression, pul-
monary morphogenesis was markedly perturbed with the very
rapid appearance of localized cystic lung malformations. The type
of malformation observed was developmental stage and loca-
tion dependent, with the spectrum ranging from macrocystic
Figure 2. Spatial dependence of cystic malfor-
mations. Fetal injections of viral vector targeted
proximal versus distal areas of the pulmonary
tree and lungs were analyzed at E21.5. Early
proximal injections of AdGFP-FGF10 (a–c) in-
duced the formation of a few large cysts within
the central lung parenchyma easily detectable
by macroscopic inspection. Early distal injec-
tions of AdGFP-FGF10 (d–f ) induced the forma-
tion of several large cysts visible in the periphery
of the lung, but the cysts were smaller than with
proximal injections. Late FGF10 gene transfer
(g–l ) induced the formation of small cysts that
were barely macroscopically detectable. Once
again, the cysts were larger with proximal
injections (g-i ) than distal injections ( j–l ). The
overall affected area in late injections was more
restricted than that inearly injections. In all
groups, GFP expression (b, e, h, k) coincided
with the location of the cysts and the malfor-
mations were well demarcated from the adja-
cent normal lung parenchyma. Scale bars
correspond to 500 mm.
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malformations lined by predominantly bronchial epithelium, to
microcystic malformations lined by predominantly alveolar epi-
thelium. The malformations were detectable by prenatal ultra-
sound examination within 24 hours after vector injection, and
persisted until at least 1 week after birth. Whether examined
grossly, by pre or postnatal imaging, or microscopically, the
malformations appeared remarkably similar to the spectrum of
human malformations characterized as congenital cystic adeno-
matoid malformation (CCAM).
The present study differs from previous studies examining the
effect of FGF10 overexpression during lung development in
several important ways. Expression of FGF10 in this study was
focal rather than diffuse, and was expressed in interstitial cells
rather than ectopically from respiratory epithelium. In our pre-
vious study (20) assessing the distribution of marker gene
expression after intraparenchymal injection, we demonstrated
that gene expression could be limited to a small area of lung
parenchyma by limiting the volume of injection, and that
expression was confined to the interstitial compartment of the
lung with no demonstrable co-localization with SP-B–expressing
epithelial cells. This distribution of expression was confirmed in
this study by both GFP immunohistochemistry and wISH for
FGF10. Another important difference is that the expression in
this study was relatively transient. This was due to the use of
adenoviral vector allowing rapid onset of expression with peak
expression occurring approximately 24 hours after injection. The
expression profile of FGF10 documented in this study is in good
agreement with our previous study (20) in which quantitative
PCR was used to assess GFP mRNA expression using the
AdGFP control vector. The rapid diminution of transgene
expression in both studies is consistent with the known episomal
location of adenoviral gene expression, the small volume of
vector administered (25 nl), and the rapid proliferation of fetal
lung tissue. The fact that we observed rapid formation of the
cystic lesions and that they persisted, supports the hypothesis that
FGF10 is involved in the early inductive events in CCAM
formation and that continued presence of FGF10 is not neces-
sarily required in the natural evolution of CCAMmalformations.
Although speculative, our results can be interpreted in the
context of current models of FGF10 involvement in branching
Figure 3. Histologic charac-
terization of cystic malforma-
tions. Specimens from fetuses
injected in the proximal and
distal lung parenchyma at
E15.5 (f–o) and E18.5 (p–y)
were analyzed at E21.5. Lungs
injected at E15.5 targeting the
proximal area of bronchopul-
monary tree presented large
cysts encircled by a well-de-
fined muscular wall composed
of two to three cell layers (g).
Cysts were lined by tall colum-
nar pseudostratified epithe-
lium (f ) and the majority of
the cells lining the cysts were
positive for CCSP (h), with very
few cells expressing proSP-C
(i ). In contrast, lungs injected
into the distal parenchyma at
E15.5 demonstrated several
large cysts that were lined with
cuboidal to tall columnar epi-
thelium (k). Subepithelial
smooth muscle fibers could
be detected forming an in-
complete layer (l ). Cystic epi-
thelium was predominantly
positive for pro–surfactant pro-
tein (SP)-C (n), whereas CCSP immunostaining revealed a sharp boundary between positive and negative areas (m). Cystic malformations in fetuses
injected at E15.5 were separated by thin septae containing a small amount of interstitial tissue. Injections at E18.5 resulted in relatively small cysts
lined by cuboidal epithelium and separated by a moderate to abundant amount of loose mesenchymal type of interstitium (p, u). Cystic
malformations caused by proximal injections contained few CCSP-positive cells (r), rare proSP-C-positive cells (s) and an incomplete subepithelial
smooth muscle layer (q). Cystic malformations secondary to distal injections were lined by proSP-C positive cells (x) and scattered smooth muscle
cells were present (v). In all groups, GFP positive cells were restricted to the interstitial compartment of lung parenchyma ( j, o, t, y). In all groups
cartilage and skeletal muscle were absent. Scale bars correspond to 100 mm for hematoxylin and eosin, a-smooth muscle actin, and CCSP and
50 mm for pro–SP-C and GFP immunostaining.
TABLE 1. HISTOLOGIC CHARACTERIZATION OF CYSTIC
MALFORMATIONS
E15.5 Proximal E15.5 Distal E18.5 Proximal E18.5 Distal
Cyst size Large Large Small Small
Number of cysts Few Several Few Several
















CCSP 111 1 1/2 —
SP-C 1/2 111 — 111
Definition of abbreviations: a-SMA, a-smooth muscle actin; CCSP, Clara cell
secretory protein; E, Embryonic Day; SP-C, surfactant protein C.
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morphogenesis (27) in which FGF10 and reciprocal influences
such as Bmp4 and Spry2 regulate lung development (Figure 6).
Under normal circumstances, cross-talk between the mesen-
chyme and the endodermal epithelium regulates the spatial and
temporal gene expression for fgf10, Bmp4, and many other
morphoregulatory molecules. Highly localized expression of
fgf10 in the mesenchyme adjacent to the tip of the nascent
airway stimulates proliferation and growth outward. Simulta-
neously, FGF10 signaling induces a steady increase in Bmp4 or
other reciprocal factors transcription in epithelial cells. Bmp4
and Spry2 are inhibitory to epithelial cell proliferation/move-
ment arresting the outward movement of the developing airway
(8, 10). Branching is then induced by lateral up-regulation of
mesenchymal FGF10 inducing dichotomous branching of the
more proximal epithelium that remains responsive to FGF10.
Thus during early stages of branching morphogenesis, high
levels of mesenchymal FGF10 expression would be expected
to induce a burst of proliferation and outward migration of the
epithelium in segments of the developing airways between
branch points that would be expected to be responsive to
FGF10, with less proliferation at branch points where Bmp4
and other antagonists were expressed. While reciprocal signals
such as Bmp4 would be expected to be diffusely induced in the
epithelium, the ultimate size of the cyst would depend upon the
balance of proliferative versus inhibitory signaling. In situ
hybridization for BMP4 and for Spry2 indicated that their
regulatory action over FGF10 might not be effective in lungs
that were injected at earlier stages, because they are not con-
comitantly overexpressed. Thus, at the early time point, within
the first 24 to 48 hours when FGF10 levels are high, one would
Figure 4. FGF10 mesenchymal overex-
pression coincides with location of cystic
malformations. Lungs from injected
fetuses at E15.5 and E18.5 were analyzed
by whole mount in situ hybridization
(wISH) for fgf10, 24 hours after injection
(E16.5, f–j, and E19.5, k–o, respectively).
The macroscopic view (a, f, k) and fluo-
rescence stereomicroscopy images for
GFP (b, g, l ) are depicted alongside the
wISH images for comparison. FGF10 is
overexpressed in the mesenchyme of the
cystic area (h–j; m–o). (p) Quantitative
PCR for FGF10 in lung. FGF10 expression
of injected lungs at E15.5 was analyzed
at E16.5, E18.5, and E21.5. Quantitative
PCR was performed in PBS control,
AdGFP-FGF10 injected, and contralateral
lungs. Fgf10 mRNA levels were signifi-
cantly higher at E16.5 in AdGFP-FGF10
ipsilateral lungs versus PBS and contra-
lateral lungs. However, at E18.5 and
E21.5 FGF10 expression was not signifi-
cantly different among groups. Scale bars
correspond to 50 mm for methacrylate
sections of hybridized lungs.
Figure 5. BMP4 and Spry2 expression pattern in cystic
malformations. Lungs from injected fetuses at E15.5 and
E18.5 were analyzed by in situ hybridization (ISH) for bmp4
and spry2, 24 hours after injection (E16.5, a–d; and E19.5,
e–h, respectively). For AdGFP-FGF10 early injected lungs (b,
d) the expression pattern of BMP4 and Spry2 does not seem
altered in relation to respective controls (a, c). For AdGFP-
FGF10 late injected lungs (f, h) expression of BMP4 and
Spry2 is increased in the epithelium of the cystic malforma-
tions when compared with controls (e, g). Scale bars
correspond to 200 mm.
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expect unopposed action of FGF10 with rapid formation of
large cysts. In contrast, in late injected lungs it was clear that
expression of these two factors increase in the epithelium
surrounding cystic areas. In this case, the significant induction
of these regulatory molecules might be responsible for the
inhibitory effect on FGF10-induced proliferation, leading to the
formation of smaller cysts in late injected lungs. Also, in the
proximal airways, where fewer branch points exist, and high
columnar epithelium predominates, unopposed FGF10 signal-
ing would be predicted to result in large cysts lined by predom-
inantly bronchial epithelium. In distal airways, where multiple
branch points are already present and cuboidal epithelium pre-
dominates, smaller and more numerous cysts would form lined
by predominantly alveolar epithelium. In contrast, during the
canalicular stage of lung development only terminal branching
occurs and the distal airways are lined predominantly by cuboi-
dal epithelium which is beginning to flatten and differentiate
into type I and type II pneumocytes. Thus FGF10 overexpres-
sion might stimulate short segments of responsive epithelium
into small cyst formation but the predominant effect would be
expected to be similar to the effect of conditional FGF10 over-
expression in postnatal lungs in which differentiated adenomas
lined by abundant Type II epithelial cells form.
Ch’in and Tang identified CCAM as a pathologic entity in
1949 (27). While the pre- and postnatal natural history of CCAM
is now well defined (28, 29), the pathogenesis of CCAM remains
unknown. Diagnosis of CCAM in fetal life is usually made by
ultrasound evaluation, and typically lesions are confined to
a single lobe and can be classified as macrocystic or microcystic.
In humans, macrocystic CCAMs have large cysts (2–10 cm) that
vary in size and number with thin intervening echogenic areas.
These multiple cysts are interconnected, and typically commu-
nicate with the tracheobronchial tree. The microcystic classifi-
cation is applied to lesions that appear as a well delineated
echogenic area in the fetal lung with no macrocystic spaces being
identified. A CCAM categorization between the macrocystic
and microcystic ‘‘definition’’ is sometimes used where the cyst
spaces are present but small to moderate sized (, 2 cm) with
adjacent echogenic tissue areas (30, 31). The ultrasound and
MRI appearance, lobar distribution, and ultrasound classifica-
tion of the malformations observed in this study were strikingly
similar to human CCAM. FGF10 gene transfer during the
pseudoglandular stage resulted in macrocystic lesions by ultra-
sound classification that were confirmed by MRI evaluation at
Postnatal Day 7. A completely different ultrasound pattern was
observed when gene transfer was performed during the canalic-
ular stage—no cysts were visualized, but well-defined areas of
increased echogenicity could be identified. MRI performed on
microcystic lesions at 7 days after birth demonstrated very small
cysts with careful analysis of images. The clinical manifestations
of our induced lesions were also suggestive of human CCAM.
CCAMs may grow rapidly before birth to massive size, resulting
in extreme mediastinal shift and compromise of cardiac output
resulting in fetal heart failure (hydrops); they may cause re-
spiratory distress after birth; or they may be asymptomatic. It is
not uncommon for CCAMs to undergo a rapid growth phase,
only to decrease in size later in gestation. The same spectrum of
clinical manifestations was observed in this study ranging from
pre- or perinatal death from large, mass displacing tumors to
asymptomatic survivors.
Stocker classified CCAMs into five subtypes defined on the
basis of clinical features, macroscopic and microscopic criteria,
and the site of the defect in the tracheobronchial tree (32).
Depending on differences in cytodifferentiation, CCAM can be
Figure 6. Model of FGF10 induction of cystic
adenomatoid malformations. During the pseudo-
glandular and early canalicular phases the lung
consists of repeating branch points with terminal
growth determined by mesenchymal epithelial in-
teraction orchestrated by mesenchymal FGF10
expressed at the tips of the elongating airways. By
the model of Weaver and coworkers (10), FGF10
induces Bmp4 (or other FGF10 antagonists) in the
adjacent epithelium, which renders the epithelium
resistant to FGF10, stopping airway extension and
creating a branch point with dichotomous branch-
ing induced by lateral FGF10 stimulation of the
more proximal responsive airway epithelium. By
this model, either proximal or early FGF10 over-
expression as depicted by pink circle 1 would
stimulate a limited number of more proximal or
less differentiated responsive airway segments,
resulting in large cystic malformations. Whereas
distal FGF10 overexpression as depicted by circle 2
would stimulate a larger number of distal or more
differentiated FGF10-responsive airway segments,
respectively, resulting in a large number of smaller
cysts. The cysts would tend to enlarge until in-
duction of Bmp4 and other reciprocal factors
resulted in epithelial inhibition or the FGF10 con-
centration diminished. The lining epithelium would
be composed of the differentiated progeny of the
lining epithelium of the proximal versus distal
stimulated segment, that is, either bronchial or
alveolar type epithelium, respectively. Although
not shown in this cartoon, late FGF10 overexpres-
sion would be predicted to act on differentiated epithelium and terminally differentiated airways resulting in more adenomatous hyperplasia rather
than cystic malformation.
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divided into two major subtypes: CCAM types 1, 2, and 3,
consisting of tissue with a bronchiolar-type epithelial differen-
tiation; and a second subtype consisting of CCAM type 4, which
has an acinar-alveolar epithelial differentiation. These two
major subtypes have been hypothesized to originate at distinct
stages of lung development: the first subtype (CCAM types 1, 2,
and 3) may develop at the pseudoglandular stage, and the
second subtype (CCAM type 4) may be due to a late event that
disrupts branching of the distal acinar structures in the saccular
period (33). Our study supports this pathophysiologic hypoth-
esis. In this study we could reproduce the two histologic sub-
types of CCAM. When proximal overexpression of FGF10 was
induced during the pseudoglandular phase, we induced large
cysts lined by tall to columnar epithelium with a high density of
Clara cells and only few type II pneumocytes, resembling
bronchiolar-type epithelial differentiation. Furthermore, when
distal overexpression of FGF10 was induced during the cana-
licular phase, we observed small cysts composed of cuboidal
epithelial that were primarily type II pneumocytes, resembling
acinar epithelial differentiation.
There have been a number of efforts to characterize the
molecular basis of CCAM in surgical specimens collected in
both the pre- and postnatal periods. Cass and collaborators
demonstrated that there is increased proliferation and de-
creased apoptosis in fetal CCAMs (34). Fgf 7 gene expression
or protein production was evaluated in CCAMs requiring fetal
resection, and no differences were found when compared with
normal lungs (34). Platelet-derived growth factor-BB (PDGF-
BB) gene expression and protein production were found to be
increased in CCAMs that grew rapidly and required in utero
resection (35), but there is no evidence that this factor is the
causative factor for CCAM. Glial cell–derived neurotrophic
factor (GDNF) was another factor with abnormal expression in
epithelial cells lining CCAM cysts, suggesting a focal arrest in
lung maturation during the fetal period (36). Although abnor-
mal Hoxb-5 expression at a level typical of earlier lung de-
velopmental stages was observed in CCAM (37), it is presently
unclear what initially triggers the cascade of events that ends
with these malformations. All these studies have a common
major limitation, which is that the analysis was performed in
CCAM specimens that were surgically resected, analysis of
which is unlikely to reveal the initial inciting events. In the
present study, we have been able to evaluate in a prospective
fashion the formation of CCAM-like malformations in response
to overexpression of FGF10 in the mesenchymal compartment
of the developing lung. We have demonstrated that transient
overexpression of a single gene in a focal area of the lung is
sufficient to reproduce the spectrum of gross and histologic
features of human CCAM in a rat model. The striking similarity
of these lesions to those seen in human CCAM strongly impli-
cates mesenchymal overexpression of FGF10 in the initial
events invoking CCAM formation. Our data thus far support
FGF10 overexpression as the most important mechanistic
component of CCAM formation. However, the identity of the
primary mesenchymal perturbation that induces FGF10 over-
expression remains to be determined.
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